An evaluation of the fixed-dose combination sacubitril/valsartan for the treatment of arterial hypertension.

Expert Opinion on Pharmacotherapy
Markus WehlandDaniela Grimm

Abstract

Essential hypertension is a significant risk factor for cardiovascular disease, renal disease, and mortality with increasing prevalence. Despite the availability of various antihypertensive agents, hypertension is still poorly controlled. Therefore, new chemical compounds with antihypertensive efficacy need to be developed. The dual angiotensin II receptor-neprilysin inhibitor LCZ696 is a single molecule synthesized by co-crystallization of valsartan and the neprilysin inhibitor prodrug sacubitril (1:1 molar ratio). This review includes an overview of hypertension and the current pharmacotherapy. The authors summarize the LCZ696 drug chemistry, pharmacodynamics, pharmacokinetics, metabolism, randomized control trials (RCTs), and safety concerns. Databases searched included PubMed, Google Scholar, Embase, and ClinicalTrials.gov. LCZ696 is effective in hypertension treatment. Short-term RCTs have shown that the highest doses of LCZ696 (200 and 400 mg [q.d.]) were more effective at lowering office and ambulatory blood pressure than angiotensin II receptor blockers (ARB) alone while having a similar tolerability profile. The effects of LCZ696 on hypertensive organ damage are only sparsely investigated and so far no studies have est...Continue Reading

References

May 12, 1995·Journal of Medicinal Chemistry·G M KsanderA Trapani
Jul 31, 1998·The New England Journal of Medicine·E R LevinW K Samson
Feb 15, 2001·Circulation·M Burnier
Sep 24, 2002·International Journal of Cardiology·Andrew J S Coats
Mar 8, 2003·Hypertension·Duncan John Campbell
Apr 27, 2004·Journal of Hypertension·Patricia M KearneyJiang He
Jun 4, 2004·Expert Opinion on Investigational Drugs·Guido Boerrigter, John C Burnett
Dec 24, 2005·American Journal of Physiology. Heart and Circulatory Physiology·Aldo ClericoMichele Emdin
Nov 17, 2007·The Journal of Physiology·Robert A Rose, Wayne R Giles
Mar 4, 2008·The Journal of Sexual Medicine·Attila KunLaszlo Pajor
Aug 16, 2008·International Review of Cell and Molecular Biology·Geoffrey E Woodard, Juan A Rosado
Dec 18, 2008·Handbook of Experimental Pharmacology·Lincoln R PotterDeborah M Dickey
Jan 30, 2009·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·John B RoseEliezer Masliah
Jul 1, 2008·Journal of the American Society of Hypertension : JASH·Kailash N Pandey
Apr 20, 2010·Journal of the American Society of Hypertension : JASH·Alan H GradmanMichael A Weber
May 6, 2010·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Vasilios KotsisGianfranco Parati
Dec 16, 2010·Journal of Hypertension·Giovanni CorraoGiuseppe Mancia
Mar 29, 2011·Progress in Retinal and Eye Research·Kyoko Ohno-Matsui
May 9, 2012·International Journal of Cardiology·Hisato TakagiUNKNOWN ALICE (All-Literature Investigation of Cardiovascular Evidence) Group
Jul 1, 2012·Drug Discovery Today. Technologies
May 14, 2014·Nature Reviews. Cardiology·Nora E ZoisJens P Goetze
Sep 13, 2014·International Journal of Cardiology·Massimo Volpe
Feb 1, 2015·European Heart Journal·Nicolas VodovarAlain Cohen-Solal
Feb 20, 2015·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Sadayoshi ItoJack Zhang
Jun 16, 2015·Journal of Clinical Pharmacology·Lu GanGangadhar Sunkara
Nov 26, 2015·Nature Reviews. Nephrology·Rhonda M Cooper-DeHoff, Julie A Johnson
Dec 15, 2015·British Journal of Clinical Pharmacology·Thomas H LangenickelIris Rajman
Mar 5, 2016·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·Jimmy FlarakosJames B Mangold

❮ Previous
Next ❯

Citations

Dec 12, 2020·The Journal of Clinical Hypertension·Donna S-H LinUNKNOWN HOPE Asia Network

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Related Papers

Perspective infirmière : revue officielle de l'Ordre des infirmières et infirmiers du Québec
Guy Sabourin
American Journal of Hypertension
Jose C Peña, Luis M Ruilope
European Heart Journal
Robert M Califf
© 2021 Meta ULC. All rights reserved